100 results on '"Lim, Joseph K."'
Search Results
2. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review
3. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review
4. Reply
5. Chronic Hepatitis B Virus: What an Internist Needs to Know
6. Left Atrial Mechanics and Diastolic Function Among People Living With Human Immunodeficiency Virus (from the Veterans Aging Cohort Study)
7. Simplifying the Diagnosis and Treatment of Hepatitis B Infection: One Step for Addressing Deficits in the Care Cascade, One Leap for Elimination
8. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
9. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
10. Su1343: INCREASED COMORBIDITY BURDEN AMONG HDV INFECTION VERSUS HBV MONOINFECTION AMONG COMMERCIALLY INSURED ADULTS IN THE UNITED STATES: AN ALL-PAYER CLAIMS DATABASE ANALYSIS
11. Su1368: ADVANCED LIVER FIBROSIS AND OBESITY ARE PRIMARY RISK FACTORS FOR LONG-TERM OUTCOMES IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
12. 871: HEPATITIS DELTA AMONG COMMERCIALLY INSURED PATIENTS IN THE UNITED STATES: AN ANALYSIS OF PREVALENCE, PATIENT CHARACTERISTICS, AND SOCIOECONOMIC STATUS
13. The ALT upper reference interval debate: Blame it on the alcohol
14. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
15. AGA Rapid Review and Guideline for SARS-CoV2 Testing and Endoscopy Post-Vaccination: 2021 Update
16. Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study
17. LEFT ATRIAL STRAIN AND DIASTOLIC DYSFUNCTION AMONGST HIV-POSITIVE INDIVIDUALS: INSIGHTS FROM THE VETERANS AGING COHORT STUDY
18. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
19. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
20. The HCV Treatment Cascade by Prior Incarceration Status in Veterans With and Without HIV
21. Hepatocellular Cancer in the Absence of Viral Hepatitis: Implications for Prevention
22. AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
23. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort
24. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic
25. Budd-Chiari Syndrome
26. Spotlight: COVID-19 PPE and Endoscopy
27. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
28. Hepatitis C
29. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma
30. Pathophysiology of Hepatic Encephalopathy
31. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review
32. Reply to: “Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)”
33. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
34. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review
35. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study
36. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
37. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
38. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges
39. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
40. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment
41. American Gastroenterological Association Institute Guideline on the Role of Elastography in the Evaluation of Liver Fibrosis
42. American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection
43. Rising Healthcare Utilization and Cost of Chronic Hepatitis B: Real-World Analysis of 44,026 Chronic Hepatitis B Patients and 121,568 Matched Non-Chronic Hepatitis B Controls in the United States
44. Advancing Age and Comorbidities in Chronic Hepatitis B Patients: Results of 10-Year Longitudinal Analysis of a Diverse Population-Based Cohort of 44,026 Chronic Hepatitis B Patients in the United States
45. Higher and Rising Prevalence and Incidence of Renal Impairment and Chronic Kidney Disease in Chronic Hepatitis B Patients Compared to Matched Non-Chronic Hepatitis B Controls in the United States: Results of a Real-World Analysis
46. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy: Analysis of 11,243 Patients in a Major us Hospital Network 2012-2015
47. Prevalence of Osteoporosis and Bone Fracture was 2-Fold Higher in Chronic Hepatitis B Compared to Non-Chronic Hepatitis B Patients and Continued to Increase in the Last Decade: Results of a United States Population-Based Cohort Study
48. Hepatitis B Reactivation and Use of Pre-Emptive Hepatitis B Treatment in Cancer Patients Receiving Chemotherapy
49. Receipt and Survival Outcomes of Curative Treatment for Hepatocellular Carcinoma by Etiology in the United States
50. Longitudinal Changes in Renal Function and Comorbidities in Treatment-Naïve and Treatment-Experienced Chronic Hepatitis B Patients in an US Insured Population: Analysis of a Real-World Cohort with Long-Term Follow-Up
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.